Methdilazine

DB00902ApprovedSmall molecule

Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.

Mechanism: Methdilazine binds to the histamine H1 receptor. This blocks the action of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine.
Curator reviewed
Primary indication: Used for the symptomatic relief of hypersensitivity reactions and particularly for the control of pruritic skin disordersCurator reviewed
Formula / weight: C₁₈H₂₀N₂S · 296.43 g/mol (avg)

Resolves to

Compound

UNII4Q13LY9Z8XCAS1982-37-2ChEMBLCHEMBL1200959ChEBI6823PubChem14677KEGGD04979

Clinical / RWD

RxNorm29648ATCR06AD04PharmGKBPA164743018

Structure

InChIKeyHTMIBDQKFHUPSX-UHFFFAOYSA-NSMILESCN1CCC(CN2C3=CC=CC=C3SC3=CC=CC=C23)C1

Targets

P35367HRH1

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

130Drug interactionsStructured to mechanism, not free text

1ATC codeIncluding every combination product, plus 7 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Methdilazine, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In